If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
109.50    0.00 (0.00%)
Bid:
107.00
Ask:
112.00
Spread: 5.00 (4.673%)
Market Cap: £14.77m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Board Appointment

10 Jul 2012 08:09

RNS Number : 2592H
Revolymer PLC
10 July 2012
 



10 July 2012

Revolymer plc

("Revolymer" or "the Group")

Julian Heslop to Join the Board of Revolymer

 

Former CFO of GSK to become an Independent Non-Executive Director

 

Revolymer, the British polymer company developing products for a number of high value fast moving consumer goods ("FMCG") markets, is pleased to announce that, as a consequence of the Group's admission to the AIM Market today, the appointment of Julian Heslop to the Board has now become effective.

 

Julian served as Chief Financial Officer of GlaxoSmithKline plc ("GSK") between April 2005 and March 2011. He was also Chairman of ViiV Healthcare Limited until March 2011. He served as Senior Vice President, Operations Controller of GSK between January 2001 and March 2005 and as Financial Controller of Glaxo Wellcome plc from April 1998 to December 2000. Prior to this, Julian had senior finance roles at Grand Metropolitan plc and Imperial Brewing and Leisure. He is a Fellow of the Institute of Chartered Accountants in England and Wales.

 

Julian Heslop, commenting on his appointment said, "I am delighted to be joining the Board of Revolymer. I look forward to playing an active role as the Group seeks to generate significant value from its broad product pipeline by signing a number of licensing deals with important players in the FMCG markets it is targeting."

 

Jack Keenan, Chairman of Revolymer commenting on today's announcement said, "Julian's decision to join the Board of Revolymer, upon its Admission to AIM, is an important endorsement of the Group's technology and the market opportunities that it has chosen to pursue. His financial knowledge and experience in both pharmaceutical and FMCG markets will be extremely valuable as the company seeks to develop its business."

 

Further information on Julian Spenser Heslop as required by AIM Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies is to be found in paragraph 4 of Part VI of the Group's Admission Document which was published on 4 July 2012 and available at www.revolymer.com

 

 

Ends

 

 

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

 

Panmure Gordon (UK) Limited

+44 (0) 20 7459 3600

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

 

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Ginny Pulbrook / David Dible

 

About Revolymer

 

Revolymer® is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the confectionery chewing gum and medicated chewing gum (together "gum") markets; and in coatings & adhesives, household products and personal care (together "consumer specialties").

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOARLMATMBAMBTT
Date   Source Headline
15th May 20151:17 pmRNSHolding(s) in Company
11th May 20157:05 amRNSDirector Declaration
5th May 20157:01 amRNSDirector/PDMR Shareholding
13th Apr 20157:00 amRNSNotice of AGM
30th Mar 20157:00 amRNSPreliminary Results
24th Mar 20157:15 amRNSDirector Declaration
9th Jan 20157:00 amRNSBlocklisting Interim Review
5th Jan 201512:00 pmRNSTotal Voting Rights
11th Dec 20147:00 amRNSHolding(s) in Company
10th Nov 20147:00 amRNSPatent Infringement Settled and Discontinued
10th Oct 20144:22 pmRNSTotal Voting Rights
29th Sep 20147:00 amRNSInterim Results
25th Sep 20147:00 amRNSGlobal licence signed with Solvay
26th Aug 20147:00 amRNSNew CEO start date confirmed
9th Jul 20147:00 amRNSBlocklisting Interim Review
4th Jul 20147:00 amRNSAppointment of Chief Executive Officer
2nd Jul 20147:00 amRNSTotal Voting Rights
23rd Jun 20147:01 amRNSNotification of Major Interest in Shares
23rd Jun 20147:00 amRNSNotification of Major Interest in Shares
9th Jun 20147:00 amRNSUS supply agreement for nicotine chewing gum
3rd Jun 20147:00 amRNSTotal Voting Rights
22nd May 201412:34 pmRNSResult of AGM
30th Apr 20143:16 pmRNSNotification of Major Interest in Shares
24th Apr 20147:00 amRNSAward under Long Term Incentive Plan
23rd Apr 201412:45 pmRNSNotification of Major Interest in Shares
23rd Apr 20147:00 amRNSNotice of AGM
22nd Apr 201411:58 amRNSTotal Voting Rights
14th Apr 20147:00 amRNSAward of Technology Strategy Board funding
31st Mar 20147:00 amRNSPreliminary Results
3rd Mar 20147:00 amRNSTotal Voting Rights
30th Jan 201411:39 amRNSBlock Listing
27th Jan 20147:00 amRNSDirectorate Change
24th Jan 20144:46 pmRNSHolding(s) in Company
10th Jan 20147:00 amRNSBlock Listing Six Monthly Return
20th Nov 20137:00 amRNSMarketing approval of nicotine gum in Europe
17th Oct 20137:00 amRNSSupply and Distribution Agreement with Amma Polska
11th Oct 20137:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Sep 20137:00 amRNSInterim Results
1st Aug 20137:00 amRNSTotal Voting Rights
22nd Jul 20137:00 amRNSAward of contract to supply nicotine gum
15th Jul 201312:20 pmRNSChange of Registered Office
9th Jul 20137:00 amRNSBlocklisting Interim Review
28th May 20132:02 pmRNSResult of AGM
17th Apr 20134:47 pmRNSHolding(s) in Company
17th Apr 20137:00 amRNSDirector's Dealings
9th Apr 20137:00 amRNSPositive test results for encapsulation technology
22nd Mar 20137:00 amRNSNotice of AGM and Posting of Annual Report
13th Mar 20137:00 amRNSPreliminary Results
1st Mar 20137:00 amRNSTotal Voting Rights
1st Feb 20132:42 pmRNSNotice of patent infringement proceedings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.